Published in Clin Infect Dis on August 13, 2004
Mitochondrial DNA haplogroups influence AIDS progression. AIDS (2008) 1.29
A review of the toxicity of HIV medications. J Med Toxicol (2014) 1.19
Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naive patients: a concordance cross-sectional study. Virol J (2009) 1.10
Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women. Pediatrics (2009) 1.06
Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV. J Infect Dis (2010) 1.03
Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother (2007) 0.95
HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue. J Infect Dis (2012) 0.92
Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress. HIV Med (2011) 0.91
Zidovudine exposure in HIV-1 infected Tanzanian women increases mitochondrial DNA levels in placenta and umbilical cords. PLoS One (2012) 0.84
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. J Infect Dis (2012) 0.83
Determinants of epidermal nerve fibre density in antiretroviral-naïve HIV-infected individuals. HIV Med (2012) 0.83
Upregulation of mitochondrial gene expression in PBMC from convalescent SARS patients. J Clin Immunol (2006) 0.79
Blood cell respirometry is associated with skeletal and cardiac muscle bioenergetics: Implications for a minimally invasive biomarker of mitochondrial health. Redox Biol (2016) 0.77
Intracellular expression of Tat alters mitochondrial functions in T cells: a potential mechanism to understand mitochondrial damage during HIV-1 replication. Retrovirology (2015) 0.77
Nicotine mediates expression of genes related to antioxidant capacity and oxidative stress response in HIV-1 transgenic rat brain. J Neurovirol (2015) 0.77
Pathogenic mechanisms of mitochondrial DNA depletion in patients with HIV-1 infection. Clin Infect Dis (2005) 0.75
Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in Accra. AIDS Res Treat (2013) 0.75
Monocyte bioenergetic function is associated with body composition in virologically suppressed HIV-infected women. Redox Biol (2017) 0.75
HIV-1 promonocytic and lymphoid cell lines: an in vitro model of in vivo mitochondrial and apoptotic lesion. J Cell Mol Med (2016) 0.75
Fate of microglia during HIV-1 infection: From activation to senescence? Glia (2016) 0.75
Oxidative mitochondrial DNA damage in peripheral blood mononuclear cells is associated with reduced volumes of hippocampus and subcortical gray matter in chronically HIV-infected patients. Mitochondrion (2016) 0.75
Evidence of Subclinical mtDNA Alterations in HIV-Infected Pregnant Women Receiving Combination Antiretroviral Therapy Compared to HIV-Negative Pregnant Women. PLoS One (2015) 0.75
Blood-based bioenergetic profiling: A readout of systemic bioenergetic capacity that is related to differences in body composition. Redox Biol (2017) 0.75
Adipose Tissue in HIV Infection. Compr Physiol (2017) 0.75
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
Double-blind clinical trial to compare autologous fat grafts versus autologous fat grafts with PDGF: no effect of PDGF. Plast Reconstr Surg (2014) 3.21
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med (2003) 2.64
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS (2004) 2.39
[Antiretroviral therapy of HIV infection: duration and reasons for changing the first therapeutic regimen in 518 patients]. Med Clin (Barc) (2006) 2.14
Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr (2004) 2.11
Transmission of HIV-1 from an obstetrician to a patient during a caesarean section. AIDS (2006) 2.06
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]. Enferm Infecc Microbiol Clin (2011) 2.03
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]. Enferm Infecc Microbiol Clin (2012) 2.02
[Main training in medical specialties: a challenge of the present for a better health system]. Med Clin (Barc) (2006) 2.02
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]. Med Clin (Barc) (2005) 1.78
Forwarding techniques for IP fragmented packets in a real 6LoWPAN network. Sensors (Basel) (2011) 1.73
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). J Acquir Immune Defic Syndr (2008) 1.68
Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS (2006) 1.65
A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med (2013) 1.62
Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet (2004) 1.59
Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003). Enferm Infecc Microbiol Clin (2006) 1.59
Statistical reviewers improve reporting in biomedical articles: a randomized trial. PLoS One (2007) 1.49
Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin. J Acquir Immune Defic Syndr (2007) 1.47
The effects of sepsis on mitochondria. J Infect Dis (2011) 1.45
[Postgraduate medical training in Spain (MIR): a proposal for the adaptation to the sanitary model requirements]. Med Clin (Barc) (2008) 1.43
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]. Enferm Infecc Microbiol Clin (2004) 1.42
Considerations about the value of sonography for the measurement of regional body fat. AIDS (2006) 1.41
[Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia]. Med Clin (Barc) (2006) 1.41
Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis (2004) 1.41
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther (2011) 1.41
Core competencies in internal medicine. Eur J Intern Med (2012) 1.39
Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis (2002) 1.39
[Treatment of symptomatic hyperlactatemia and lactic acidosis in HIV+ patients under nucleoside reverse transcriptase inhibitors]. Med Clin (Barc) (2005) 1.38
Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother (2006) 1.38
Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology (2009) 1.34
Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother (2007) 1.30
Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy. Antivir Ther (2003) 1.29
Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr (2008) 1.24
Carbon monoxide specifically inhibits cytochrome c oxidase of human mitochondrial respiratory chain. Pharmacol Toxicol (2003) 1.24
A new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized study. PLoS One (2011) 1.15
A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis (2011) 1.15
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]. Enferm Infecc Microbiol Clin (2013) 1.11
Therapeutic vaccines against HIV infection. Hum Vaccin Immunother (2012) 1.11
Differential gene expression indicates that 'buffalo hump' is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy. AIDS (2008) 1.11
[Effect of statistical review on manuscript quality in Medicina Clínica (Barcelona): a randomized study]. Med Clin (Barc) (2003) 1.10
Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Rev (2012) 1.05
Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis (2004) 1.05
A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum (2002) 1.03
HIV integrase inhibitors: a new era in the treatment of HIV. Expert Opin Pharmacother (2015) 1.02
Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis (2004) 1.02
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Antivir Ther (2004) 1.01
Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther (2004) 1.01
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr (2009) 0.99
Lipodystrophy and quality of life of HIV-infected persons. AIDS Rev (2008) 0.97
Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS (2011) 0.97
Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study. J Antimicrob Chemother (2012) 0.97
Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³. AIDS Res Hum Retroviruses (2013) 0.96
Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis (2006) 0.96
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Clin Infect Dis (2008) 0.95
Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1. J Virol (2012) 0.95
B-function expression in the flower center underlies the homeotic phenotype of Lacandonia schismatica (Triuridaceae). Plant Cell (2010) 0.95
Mitochondrial damage in adipose tissue of untreated HIV-infected patients. AIDS (2011) 0.94
Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther (2005) 0.93
Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr (2007) 0.93
Impact of lipodystrophy on the quality of life of HIV-1-infected patients. J Acquir Immune Defic Syndr (2002) 0.93
Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn. AIDS (2012) 0.93
Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. J Clin Psychopharmacol (2007) 0.92
Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine. J Acquir Immune Defic Syndr (2004) 0.92
Mitochondrial studies in HAART-related lipodystrophy: from experimental hypothesis to clinical findings. Antivir Ther (2005) 0.92
Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir Ther (2004) 0.91